鼻分泌物嗜酸细胞检测评价布地奈德喷鼻剂治疗变应性鼻炎疗效分析

摘要

Objective To investigate the changes of detection of eosinophil in nasal secretion in patients with allergic rhinitis before and after Budesonide nasal spray therapy.Methods A total of 76 cases of allergic rhinitis patients were divided into mild group and moderate-severe group according to the clinical symptoms,and they were treated with Budesonide nasal spray.Visual analogue scale(VAS) score changes were recorded before and after treatment in patients with nasal symptoms,the percentage of eosinophils(EOS%) in nasal secretions was measured before and 2,4 and 6 weeks after treatment,and the results were analyzed.Results After 2 weeks treatment with Budesonide nasal spray,the VAS score of patients was significantly lower than before,the difference was statistically significant(P<0.05).Before treatment,the EOS% in the nasal secretions of the moderate-severe group was significantly higher than that of mild group(P<0.05),and the EOS% in nasal secretions was positively correlated with the severity of the disease.After 2,4 and 6 weeks treatment,the nasal secretions of EOS% patients decreased significantly compared with before treatment(P<0.05);and the longer the treatment time,the more obvious the decrease of EOS% in nasal secretions,the difference was statistically significant(P<0.05).Conclusion EOS% in nasal secretions may reflect the severity of allergic rhinitis patients.Budesonide nasal spray can effectively improve clinical symptoms and reduce the level EOS% in nasal secretions.EOS% in nasal secretions may be used as one of the methods to evaluate the therapeutic effect of AR drugs.%目的 探讨鼻分泌物嗜酸细胞(EOS)检测评价布地奈德喷鼻剂治疗变应性鼻炎(AR)前、后的疗效.方法 选择该院门诊76例AR患者作为研究对象,根据患者临床症状将其分为轻度、中-重度组.采用布地奈德喷鼻剂进行治疗,记录治疗前、后患者鼻部症状的视觉模拟量表(VAS)评分,检测治疗前及治疗2、4、6周后鼻分泌物中的EOS所占百分数(EOS%),并对结果进行分析.结果 布地奈德喷鼻剂治疗2周后AR患者VAS评分较治疗前明显降低,差异有统计学意义(P<0.05).治疗前,中-重度患者鼻分泌物中的EOS%明显高于轻度患者,差异有统计学意义(P<0.05),鼻分泌物中的EOS%与疾病严重程度呈正相关.治疗2、4周和6周后患者鼻分泌物EOS%较治疗前明显下降,差异有统计学意义(P<0.05),且治疗时间越长,鼻分泌物中的EOS%下降越明显,差异有统计学意义(P<0.05).结论 鼻分泌物EOS%可反映AR患者病情的严重程度,而布地奈德喷鼻剂治疗可有效改善患者临床症状,降低患者鼻分泌物EOS%水平,因此,鼻分泌物EOS%检测可作为评价AR药物疗效的方法之一.